[ET Net News Agency, 11 June 2021] Luye Pharma Group Ltd. (02186) said the marketing
authorization application for the Class 1 new chemical entity (NCE) product Anshufaxine
Hydrochloride Extended-release Tablets (LY03005) under development by the group has been
accepted by the Centre for Drug Evaluation of the National Medical Products Administration
in the People's Republic of China.
LY03005 is a new antidepressant agent developed by the new therapeutic entity/new
chemical entity (NTE/NCE) technology platform of the group. Studies reveal that
Anshufaxine is a serotonin (5-HT)-norepinephrine (NE)-dopamine (DA) reuptake inhibitor
(SNDRIs). (RC)